Navegar por autor "Antela López, Antonio"

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

2012- Antela López, Antonio

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

2019- Alejos, B.; Suarez-Garcia, I.; Bisbal, O.; Iribarren, J. A.; Asensi, V.; [et al.]

CONTROL DE FACTORES DE RIESGO CARDIOVASCULAR EN PACIENTES CON INFECCIÓN POR VIH Y CARDIOPATÍA ISQUÉMICA

2014- Antela López, Antonio; Martínez Braña, Lucía; Mateo Mosquera, Lara María; Bermúdez Ramos, María; Losada Arias, Elena [et al.]

Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms

2012- Antela López, Antonio

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial

2015- Antela López, Antonio; Losada Arias, Elena

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

2013- Antela López, Antonio

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

2015- Mariño Callejo, Ana Isabel; Miralles Alvarez, María Celia; Ocampo Hermida, Antonio; Antela López, Antonio

Eficacia de dolutegravir en pacientes naive. Estudios SPRING-1, SPRING-2, SINGLE y FLAMINGO

2015- Antela López, Antonio

EVOLUCIÓN DE LA PRESENTACIÓN CLÍNICA EN EL DIAGNÓSTICO DE LA INFECCIÓN POR VIH EN LA ÚLTIMA DÉCADA

2014- Antela López, Antonio; Martínez Braña, Lucía; Mateo Mosquera, Lara María; Losada Arias, Elena

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

2014- Miralles Alvarez, María Celia; Antela López, Antonio

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. A Cohort Study

2020- Del Amo, Julia; Polo, Rosa; Moreno, Santiago; Díaz, Asunción; Martínez, Esteban; [et al.]

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

2014- Antela López, Antonio

Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status

2011- Mariño Callejo, Ana Isabel; Antela López, Antonio

LipoDDx: a mobile application for identification of rare lipodystrophy syndromes

2020- Araujo Vilar, David; Fernández Pombo, Antía; Rodríguez Carnero, María Gemma; Martínez Olmos, Miguel Ángel; Cantón Blanco, Ana; [et al.]

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study

2014- Antela López, Antonio

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study

2014- Antela López, Antonio

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

2015- Mariño Callejo, Ana Isabel; Ocampo Hermida, Antonio; Antela López, Antonio

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

2020- Murray, M.; Antela López, Antonio; Mills, A.; Huang, J.; Jäger, H.; [et al.]

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study

2015- Antela López, Antonio; Suárez Dono, Francisco Javier

Redefining therapeutic success in HIV patients: an expert view

2021- Antela López, Antonio; Rivero, A.; Llibre, J. M.; Moreno, S.

Repositorio digital RUNA

Navegar por autor "Antela López, Antonio"

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir ﻿

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors ﻿

CONTROL DE FACTORES DE RIESGO CARDIOVASCULAR EN PACIENTES CON INFECCIÓN POR VIH Y CARDIOPATÍA ISQUÉMICA ﻿

Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms ﻿

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial ﻿

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection ﻿

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial ﻿

Eficacia de dolutegravir en pacientes naive. Estudios SPRING-1, SPRING-2, SINGLE y FLAMINGO ﻿

EVOLUCIÓN DE LA PRESENTACIÓN CLÍNICA EN EL DIAGNÓSTICO DE LA INFECCIÓN POR VIH EN LA ÚLTIMA DÉCADA ﻿

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014) ﻿

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. A Cohort Study ﻿

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen ﻿

Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status ﻿

LipoDDx: a mobile application for identification of rare lipodystrophy syndromes ﻿

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study ﻿

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study ﻿

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study ﻿

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks ﻿

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study ﻿

Redefining therapeutic success in HIV patients: an expert view ﻿

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

CONTROL DE FACTORES DE RIESGO CARDIOVASCULAR EN PACIENTES CON INFECCIÓN POR VIH Y CARDIOPATÍA ISQUÉMICA

Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

Eficacia de dolutegravir en pacientes naive. Estudios SPRING-1, SPRING-2, SINGLE y FLAMINGO

EVOLUCIÓN DE LA PRESENTACIÓN CLÍNICA EN EL DIAGNÓSTICO DE LA INFECCIÓN POR VIH EN LA ÚLTIMA DÉCADA

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. A Cohort Study

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status

LipoDDx: a mobile application for identification of rare lipodystrophy syndromes

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study

Redefining therapeutic success in HIV patients: an expert view